Covid-19 man­u­fac­tur­ing roundup: Emer­gent starts clean-up ef­fort af­ter dis­as­trous Form 483; Eli Lil­ly ex­pands li­cens­es for In­di­an part­ners

Af­ter botch­ing mil­lions of dos­es of a Covid-19 vac­cine, be­ing over­tak­en by the FDA and shak­ing up its lead­er­ship team, Emer­gent has com­plet­ed a com­pre­hen­sive qual­i­ty en­hance­ment plan, the com­pa­ny an­nounced Wednes­day. The move comes af­ter the FDA is­sued the firm a dis­as­trous Form 483 that not­ed nu­mer­ous qual­i­ty con­trol and train­ing is­sues.

“We have al­ready start­ed mak­ing im­prove­ments and we are ful­ly com­mit­ted to mak­ing the nec­es­sary short — and long — term en­hance­ments to meet or ex­ceed FDA stan­dards,” the state­ment said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER